e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD
J. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, A. Church (Chapel Hill, Minneapolis, Research Triangle Park, United States Of America; Uxbridge, United Kingdom)
Source:
Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Session:
Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Session type:
Thematic Poster Session
Number:
760
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, A. Church (Chapel Hill, Minneapolis, Research Triangle Park, United States Of America; Uxbridge, United Kingdom). Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD. Eur Respir J 2013; 42: Suppl. 57, 760
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Once-daily QVA149 has a good safety profile in patients with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Doxofylline: Efficacy and safety in complex treatment of COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept